In a landmark legal confrontation that strikes at the heart of the American pharmaceutical supply chain, three of the nation’s most prominent health systems have launched a coordinated legal offensive against CVS Health. The litigation, filed this week, alleges that the pharmacy giant and its pharmacy benefit manager (PBM) subsidiary, CVS Caremark, systematically diverted approximately $250 million in savings intended for safety-net providers under the federal 340B Drug Pricing Program.
Mount Sinai, Michigan Medicine, and the University of Kansas Health System—powerhouses in clinical care and research—filed separate but substantively aligned lawsuits on Monday. The move marks an escalation in the long-standing tension between nonprofit hospital systems and the powerful intermediaries that control drug distribution and reimbursement in the United States.
The Core Allegation: "Spread Pricing" and the 340B Gap
At the center of the dispute is the 340B Drug Pricing Program, a federal initiative enacted by Congress in 1992. The program was designed as a lifeline for "safety-net" providers—hospitals that serve a high volume of low-income, uninsured, or underinsured patients. By allowing these institutions to purchase outpatient drugs at steeply discounted prices, the program provides the necessary financial cushion to expand services, offer charity care, and maintain operations in underserved regions.
The health systems allege that CVS, leveraging its position as both a PBM and a pharmacy operator, implemented a practice known as "spread pricing." According to the complaints, CVS Caremark utilized reimbursement structures that intentionally retained the significant gap between what insurers paid for drugs and the lower amounts eventually passed on to the 340B providers.
By effectively keeping this margin, the plaintiffs argue, CVS redirected funds that Congress explicitly intended for the benefit of vulnerable patient populations. The litigation estimates that between 2020 and 2025, these practices resulted in roughly $250 million of diverted savings—funds that the hospitals claim should have been reinvested into community health initiatives.
A Chronology of the Conflict
The tension between these health systems and CVS is not a recent development. The legal filings suggest a pattern of friction that has simmered for years, characterized by failed negotiations and, in at least one instance, a breakdown of contractual trust.
- 2020–2025 (The Alleged Diversion Window): The plaintiffs assert that throughout this five-year period, CVS’s reimbursement strategies consistently eroded the value of the 340B savings, keeping the "spread" as corporate profit.
- Pre-Litigation Negotiations: Representatives from the University of Kansas Health System noted that they had previously attempted to resolve these financial discrepancies through direct communication with CVS, to no avail.
- The Audit Refusal: A critical inflection point occurred when the University of Kansas Health System attempted to exercise its contractual right to conduct an audit of CVS’s practices. According to Dan Peters, general counsel for the health system, CVS denied the audit and subsequently terminated their 340B agreement entirely.
- Monday, April 2026: The three health systems filed their respective lawsuits, signaling a shift from private negotiation to public, high-stakes litigation.
Supporting Data and the PBM Model
To understand the weight of these lawsuits, one must look at the mechanics of Pharmacy Benefit Managers (PBMs). PBMs act as the "middlemen" in the drug supply chain, negotiating rebates and discounts with manufacturers and setting reimbursement rates for pharmacies.
Critics, including the American Hospital Association and various state legislatures, have long argued that the PBM model lacks transparency. "Spread pricing" occurs when a PBM charges a health plan more for a prescription drug than it pays the pharmacy, pocketing the difference. When this mechanism is applied to 340B drugs, the hospital argues that the "discount" mandated by the federal government is effectively being intercepted by the PBM before it can reach the hospital’s bottom line.
The $250 million figure cited by the plaintiffs represents a massive loss of potential revenue that could have been used for:
- Expanded Charity Care: Providing free or discounted medication to patients without insurance.
- Infrastructure Investment: Upgrading clinics in rural or impoverished urban areas.
- Specialized Medical Services: Funding oncology, pediatric, or maternal health programs that often operate at a loss.
Official Responses and Legal Stance
The legal team representing the plaintiffs, led by Jonathan Levitt of the law firm Frier Levitt, has framed the case as a moral and legislative imperative.
"CVS Health’s mission statement commits the company to lowering the cost of care and improving the health and well-being of those it serves," Levitt stated on Thursday. "What our complaints allege is the opposite: that behind the scenes, CVS systematically diverted funds Congress specifically designated to help safety-net hospitals care for the most vulnerable Americans—and pocketed them as corporate profit."
The hospitals have been clear in their objectives. A spokesperson for Mount Sinai noted that the lawsuit is an effort to ensure that hospitals "are not wrongly skimmed off by for-profit intermediaries," emphasizing the necessity of protecting the integrity of the 340B program.
Conversely, CVS Health has remained largely silent on the specific allegations. As of the time of publication, a spokesperson for the company did not respond to requests for comment from MedCity News. This silence, while standard in active litigation, leaves a vacuum in the public narrative that the plaintiffs are aggressively filling with allegations of corporate greed and systemic obstruction.
The Broader Implications for the Healthcare Industry
The outcome of this legal battle could send shockwaves throughout the U.S. healthcare system, potentially triggering a wave of similar lawsuits from other 340B-eligible hospitals.
1. Regulatory Scrutiny of PBMs
This case aligns with growing bipartisan interest in Washington regarding PBM transparency. If the courts find that CVS’s actions violated the intent of the 340B program, it could provide the political momentum necessary for federal legislation aimed at curbing spread pricing or mandating greater financial transparency for PBMs.
2. The Future of 340B Partnerships
The termination of the agreement with the University of Kansas Health System serves as a warning to other hospitals. If large, prestigious health systems are unable to secure fair terms with major PBMs, smaller rural hospitals—which are often more reliant on 340B funds for survival—may be at even greater risk of losing access to the program or being forced into unfavorable contracts.
3. Corporate Responsibility vs. Profit Maximization
This case highlights the fundamental tension between the mission-driven mandate of nonprofit hospitals and the profit-maximization goals of publicly traded pharmacy corporations. As the legal discovery process begins, the public may get a rare look into the opaque financial mechanisms that dictate how much patients pay for their medication and how much hospitals receive for the services they provide.
4. Impact on Patient Care
Ultimately, the legal and financial implications are secondary to the impact on patient care. If the health systems succeed in recovering these funds, the money is legally and ethically earmarked for community benefit. Conversely, if the courts rule in favor of CVS, the "spread pricing" model may be legally cemented, potentially limiting the ability of hospitals to maintain their safety-net status in an era of rising drug costs.
As the litigation proceeds, the healthcare sector will be watching closely. Whether this becomes a turning point for PBM regulation or remains an isolated dispute will depend on the strength of the evidence presented by Mount Sinai, Michigan Medicine, and the University of Kansas. For now, the case stands as a reminder of the complex, often adversarial relationship between the institutions that provide care and the corporations that facilitate the delivery of the drugs that make that care possible.
